Free Trial
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

Aytu BioPharma logo
$2.00 +0.03 (+1.52%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$2.01 +0.01 (+0.30%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aytu BioPharma Stock (NASDAQ:AYTU)

Key Stats

Today's Range
$1.95
$2.02
50-Day Range
$1.00
$2.59
52-Week Range
$0.95
$2.99
Volume
162,427 shs
Average Volume
367,963 shs
Market Capitalization
$17.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Aytu BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

AYTU MarketRank™: 

Aytu BioPharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 818th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Aytu BioPharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aytu BioPharma is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aytu BioPharma is -2.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aytu BioPharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.96% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 43.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Aytu BioPharma does not currently pay a dividend.

  • Dividend Growth

    Aytu BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.96% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 43.72%, indicating that investor sentiment is improving significantly.
  • Search Interest

    2 people have searched for AYTU on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of Aytu BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 33.49% of the stock of Aytu BioPharma is held by institutions.

  • Read more about Aytu BioPharma's insider trading history.
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Stock News Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
See More Headlines

AYTU Stock Analysis - Frequently Asked Questions

Aytu BioPharma's stock was trading at $1.70 on January 1st, 2025. Since then, AYTU stock has increased by 17.6% and is now trading at $2.00.
View the best growth stocks for 2025 here
.

Aytu BioPharma Inc. (NASDAQ:AYTU) announced its quarterly earnings data on Wednesday, May, 14th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.37. The firm had revenue of $18.45 million for the quarter, compared to analysts' expectations of $13.74 million. Aytu BioPharma had a net margin of 2.37% and a trailing twelve-month return on equity of 3.51%.
Read the conference call transcript
.

Aytu BioPharma's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aytu BioPharma's top institutional investors include Stonepine Capital Management LLC (7.52%) and Armistice Capital LLC (0.93%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka.
View institutional ownership trends
.

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

Last Earnings
5/14/2025
Today
6/22/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.84 million
Pretax Margin
-0.78%

Debt

Sales & Book Value

Annual Sales
$81 million
Price / Cash Flow
N/A
Book Value
$4.64 per share
Price / Book
0.43

Miscellaneous

Free Float
8,654,000
Market Cap
$17.96 million
Optionable
Not Optionable
Beta
0.05
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:AYTU) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners